The ANR supports our efforts in drug discovery for Myotonic Dystrophy type 1

Nov 25, 2021 | Short news

Ksilink is happy to announce the initiation of the ANR funded project “Target-agnostic drug discovery approaches for neuromuscular diseases (TREAD)”. This project is supporting our ongoing collaborative efforts with Prof. Cécile Martinat’s team from INSERM at I-Stem and the team around Prof. Denis Furling from the Institut de Myologie with the aim to identify novel chemical compounds on the basis of a screenable patient-based model for DM-1. We were very happy to welcome both Key Opinion Leaders in Strasbourg for a Kick-Off meeting on November 18th.

Share This